Clinical Trial Update: Modified Vaccine for High Risk or Low Residual Melanoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a phase 1/2 study of a modified vaccine for patients with high-risk or low residual malignant melanoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Modified melanoma vaccine

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: RECRUITING